SPI-62_DF2

DRUG2 trials

Sponsors

Sparrow Pharmaceuticals Inc.

Conditions

Cushing's SyndromePolymyalgia rheumatica (PMR)

Phase 2

SPI-62 as a Treatment for Adrenocorticotropic Hormone- dependent Cushing’s Syndrome

CompletedCTIS2024-515913-17-00

Sparrow Pharmaceuticals Inc.Cushing's Syndrome

Start: 2024-10-10End: 2025-09-01Target: 9Updated: 2025-02-03

A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR)

CompletedCTIS2024-517406-29-00

Sparrow Pharmaceuticals Inc.Polymyalgia rheumatica (PMR)

Start: 2022-07-26End: 2025-04-25Target: 72Updated: 2025-02-14